CL2022002817A1 - Inhibidores de replicación del virus de inmunodeficiencia humana - Google Patents

Inhibidores de replicación del virus de inmunodeficiencia humana

Info

Publication number
CL2022002817A1
CL2022002817A1 CL2022002817A CL2022002817A CL2022002817A1 CL 2022002817 A1 CL2022002817 A1 CL 2022002817A1 CL 2022002817 A CL2022002817 A CL 2022002817A CL 2022002817 A CL2022002817 A CL 2022002817A CL 2022002817 A1 CL2022002817 A1 CL 2022002817A1
Authority
CL
Chile
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus replication
replication inhibitors
formula
Prior art date
Application number
CL2022002817A
Other languages
English (en)
Inventor
P Gillis Eric
E Parcella Kyle
Dalwadi Gautam
D Parker Dawn
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CL2022002817A1 publication Critical patent/CL2022002817A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se expone una composición farmacéutica que comprende el compuesto de la Fórmula Ia, Fórmula Ib, Fórmula Ic o Fórmula Id, o una sal farmacéuticamente aceptable del mismo.
CL2022002817A 2020-04-15 2022-10-13 Inhibidores de replicación del virus de inmunodeficiencia humana CL2022002817A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010196P 2020-04-15 2020-04-15
US202063013576P 2020-04-22 2020-04-22

Publications (1)

Publication Number Publication Date
CL2022002817A1 true CL2022002817A1 (es) 2023-06-09

Family

ID=75581554

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002817A CL2022002817A1 (es) 2020-04-15 2022-10-13 Inhibidores de replicación del virus de inmunodeficiencia humana

Country Status (11)

Country Link
US (1) US20230149408A1 (es)
EP (1) EP4135702A1 (es)
JP (1) JP2023521460A (es)
KR (1) KR20230002629A (es)
CN (1) CN115397424A (es)
AU (1) AU2021256166B2 (es)
BR (1) BR112022020933A2 (es)
CL (1) CL2022002817A1 (es)
IL (1) IL297041A (es)
MX (1) MX2022012881A (es)
WO (1) WO2021209900A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023062559A1 (en) * 2021-10-13 2023-04-20 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863778A (zh) 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
ES2614053T3 (es) 2013-01-09 2017-05-29 Gilead Sciences, Inc. Heteroarilos de 5 miembros y su uso como antivirales
JP5860197B1 (ja) 2013-01-09 2016-02-16 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症を処置するための治療用化合物
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2016033243A1 (en) 2014-08-29 2016-03-03 Gilead Sciences, Inc. Antiretroviral agents
EP4265299A3 (en) 2016-08-19 2024-01-17 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
UY37710A (es) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ， インコーポレイテッド Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
EP3774775B8 (en) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
KR20230141905A (ko) * 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2020058844A1 (en) * 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
AU2021256166A1 (en) 2022-10-20
US20230149408A1 (en) 2023-05-18
MX2022012881A (es) 2022-11-08
BR112022020933A2 (pt) 2022-12-06
EP4135702A1 (en) 2023-02-22
WO2021209900A1 (en) 2021-10-21
AU2021256166B2 (en) 2024-05-23
KR20230002629A (ko) 2023-01-05
CN115397424A (zh) 2022-11-25
JP2023521460A (ja) 2023-05-24
IL297041A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
PE20160180A1 (es) Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos.
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana